Clutch (eggs)

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

Retrieved on: 
Monday, April 8, 2024
Arm, Retinitis pigmentosa, Disease, Patient, Lux, RP, IND, Clutch (eggs), Vaccine, Food, RHO, FDA, BLA, Pharmaceutical industry

“OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.

Key Points: 
  • “OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.
  • Until now, there has been only one marketed product to treat one of the 100 gene mutations associated with RP.
  • In the Phase 1/2 OCU400 clinical trial, a Multi-Luminance Mobility Testing (MLMT) scale was the primary functional endpoint.
  • With the initiation of the Phase 3 clinical trial, OCU400 remains on track for the 2026 BLA approval target.

Millennials Reclaim Position as Largest Group of Home Buyers

Retrieved on: 
Wednesday, April 3, 2024
Silent Generation, Millennials, Generation, Research, NAR, Generation Z, Sale, Woman, Generator, Housing, Retirement, Dream, Clutch (eggs), National Association, Gen, Real estate

Millennials have surged ahead to become the largest group of home buyers, marking a significant shift in the housing market’s demographic landscape, according to the latest report from the National Association of Realtors®.

Key Points: 
  • Millennials have surged ahead to become the largest group of home buyers, marking a significant shift in the housing market’s demographic landscape, according to the latest report from the National Association of Realtors®.
  • “The generational tug-of-war between millennials and baby boomers continued this year, with millennials rebounding to capture the largest share of home buyers,” said Dr. Jessica Lautz, NAR deputy chief economist and vice president of research.
  • Leading the charge were younger millennials, whose proportion of first-time buyers increased from 70% to 75% over the past year.
  • Forty-four percent of older millennials and 24% of Generation X (ages 44-58) were first-time buyers.

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, April 1, 2024
Research, ADHD, Psych, NDA, Sale, Cingulata, Attention deficit hyperactivity disorder, Insurance, IND, Market, Adolescence, Safety, Clutch (eggs), Poster, WFIA, FDA, Security (finance)

KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update. Highlights include capital raised from multiple sources and the addition of three independent board members.

Key Points: 
  • “Our lead asset CTx-1301 continues to impress clinical investigators and key opinion leaders as we share our Phase 3 results.
  • These tailwinds put Cingulate in a position to obtain non-dilutive capital and expand our pipeline of assets.
  • Looking ahead, Cingulate has several financial instruments in place to raise additional capital while fighting to preserve shareholder’s equity.
  • “Overall, I am very pleased with the progress made by our team in 2023 and into 2024.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Upgraded Nunyerry North Drill Results Deliver High-Grade Intercepts Up to 6.12 g/t Au

Retrieved on: 
Tuesday, March 26, 2024
Diamond, Well, NVO, Vein, Gold, ASX, Creasy, RC, Novo, Igneous intrusion, Anomaly, Outline, Estrid, TSX, IP, Aegina, Clutch (eggs), Soil, Rehabilitation, Mining

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce updated, high-grade results from the maiden reverse circulation (RC) drill program completed at Nunnery North in late 2023.

Key Points: 
  • Significant drill intercepts from the 2023 Nunyerry North program of shallow reverse circulation drilling were re-analysed by multi-pot PhotonAssay™.
  • Commenting on the high-grade results from Nunyerry North, Novo Executive Co-Chairman and Acting CEO Mike Spreadborough said
    “It is exciting to see a significant grade increase in the Nunyerry North drill results, some of which are close to surface and demonstrate the substantial upside potential of this Project.
  • Based on the results, Novo resubmitted all significant drill intercepts for multi-pot PhotonAssay™ whereby all sample material was split over multiple PhotonAssay™ pots.
  • Figure 3: Nunyerry North geological interpretation, 2023 drill hole location and new drill target areas.

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, March 12, 2024
Primary sclerosing cholangitis, Patient, PSC, Integrin, IPF, Idiopathic pulmonary fibrosis, European, Therapy, Drug development, Clutch (eggs), Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis (IPF). The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial. Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).

Key Points: 
  • The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial.
  • Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).
  • “The implementation of BEACON-IPF as an accelerated pivotal, adaptive Phase 2b/3 trial design is another example of our efficient approach to drug development,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • This facility, along with the Company’s December 31, 2023 cash and cash equivalents of $495.7 million are expected to fund Pliant through 2026.

Gen Z Driving Shift Toward Digital Tax Payments, According to New Report From ACI Worldwide

Retrieved on: 
Wednesday, March 27, 2024
Technology, Generation Z, Generation X, Finance, Fintech, Banking, Accounting, Professional Services, Baby Boomers, Millennials, Personal Finance, Digital Cash Management, Digital Assets, Payments, Software, Consumer, IRS, GM, Tax, ACI, EVP, YouGov, Partnership, PayPal Credit, TaxSlayer, Ageing, Clothing, ACIW, TurboTax, H&R Block, Clutch (eggs), PayPal, ACI Worldwide, Gen, CPA

These behaviors reflect growing mistrust of professional tax institutions and a generational shift toward personal networks and digital payment platforms.

Key Points: 
  • These behaviors reflect growing mistrust of professional tax institutions and a generational shift toward personal networks and digital payment platforms.
  • Unlike Baby Boomers, Gen Xers and even Millennials, Gen Z respondents preferred alternative payment methods (10%) and credit cards (17%).
  • Additionally, Gen Z taxpayers are several times more likely to engage sources outside of professional tax preparers.
  • “This year's findings highlight a pivotal shift towards digital and alternative payment methods, especially among Gen Z.

Unlearn’s TwinRCT Solution Update Enhances Phase 2 Trial Decision-Making Power

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Clinical Trials, Clutch (eggs), Frontotemporal dementia, Disease, Stroke, Clinical trial, Parkinson's disease, AI, ALS, Medicine, Pharmaceutical industry

Unlearn ®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0.

Key Points: 
  • Unlearn ®, a company at the forefront of AI in medicine, today announced the newest version of its TwinRCT™ solution, TwinRCT 3.0.
  • TwinRCTs are randomized clinical trials that use digital twins of trial participants—comprehensive forecasts of individual clinical outcomes—to optimize clinical trials.
  • Unlearn’s updated TwinRCT can now incorporate additional previous clinical trial data to provide an even more robust framework for Phase 2 trial evaluations, which represent a crucial stage in the drug development process.
  • The results of a case study reanalyzing a completed Alzheimer’s Disease study demonstrate that a traditional trial would require 23% more trial participants to achieve the same power as Unlearn’s updated TwinRCT.

air up®'s April Fools Campaign Sheds Light On Americans' Peeing Habits

Retrieved on: 
Tuesday, April 2, 2024
Health, Perspiration, Mental health, Fool, Joint, Drinking, Urine, Dehydration, Cognition, Water, Habit, Clutch (eggs), LOS, Sawmill

With this campaign, air up® aimed to spark a national conversation about the importance of proper hydration, particularly in light of the fact that 61% of Americans express current or past concerns about the color of their urine.

Key Points: 
  • With this campaign, air up® aimed to spark a national conversation about the importance of proper hydration, particularly in light of the fact that 61% of Americans express current or past concerns about the color of their urine.
  • Lena Jüngst, Co-Founder of air up®, explains, "Rest assured, we're not launching a pee-flavored pod.
  • The attention-grabbing tactic is part of a broader educational campaign to highlight the release of air up's® recent survey shedding light on Americans' peeing habits.
  • While the findings underscore positive awareness of urine's significance as a marker for hydration and overall health, significant gaps remain.

Wizehire's 2024 Women in Leadership Report reveals challenges fueled by a resurgence of traditional values among young adults, a widening leadership gap, and the need for DEI initiatives

Retrieved on: 
Tuesday, March 26, 2024
Face, Female, Woman, YouGov, Risk, Ageing, Perception, Lead, Private sector, Glass, Marketing, Motherhood penalty, Clutch (eggs), Workplace, Family, Parent, DEI, Nursing

HOUSTON, March 26, 2024 /PRNewswire/ -- Wizehire, an end-to-end hiring solution for growing small and medium-sized businesses, today unveiled findings from its first Women in Leadership Report, a comprehensive study exploring the evolving dynamics of women in the workplace. The report surveyed a sample size of 2,506 individuals representative of U.S. adults. The report sheds light on the changing perception of women in leadership and the barriers they face, including the "motherhood penalty" and a lack of diversity, equity, and inclusion initiatives, particularly in small businesses.

Key Points: 
  • 33% of Americans believe balancing work and family responsibilities is the biggest obstacle for women in leadership.
  • The report highlights that balancing work and family responsibilities is the biggest obstacle for women in leadership, with 33% of Americans believing so.
  • Wizehire's 2024 Women in Leadership Report highlights the changing perceptions of women in leadership, the challenges women face, and the need for greater diversity, equity, and inclusion initiatives in the workplace.
  • In addition to the survey, the report utilizes data from diverse authority sources to analyze the representation of women in leadership roles.